Jeffrey Stein bought $1.6M of IDEAYA Biosciences (IDYA)
Executed Mar 2, disclosed Mar 3, the same day.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -1.1% (delay-adjusted); from the execution session (Mar 2), -1.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jeffrey Stein (President & CEO) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in CDTX. Across 1 priced purchase filing, the average 21-session return was -1.1% from execution and -1.1% from disclosure (delay-adjusted; derived). The largest single filing was $1.6M of IDYA (50,000 sh × $32.96, as filed), executed Mar 2.
Healthcare · IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using mole…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→